Cree (CREE) Adds Marvin Riley to Board

Roth Capital Upgrades Cree (CREE) to Buy

Roth Capital analyst Craig Irwin upgraded Cree (NASDAQ: CREE) from Neutral to Buy with a price target of $150.00 (from $105.00).

The analyst comments "Upgrading Cree to Buy reflecting the consequence of mgmt's decision to start up Mohawk Valley using 8" wafers. This implies Cree's 2022 silicon... More

Cree (CREE) Misses Q2 EPS by 24c, Revenues Beat; Offer 3Q EPS/Revenue Guidance

Cree (NASDAQ: CREE) reported Q2 EPS of ($0.49), $0.24 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $127 million versus the consensus estimate of $121.6 million.

We delivered strong results for the second quarter, including sequential growth in revenue from continuing operations, underscoring the momentum we continue to see for our silicon carbide solutions, said... More

Cree (CREE) PT Raised to $100 at Deutsche Bank

Deutsche Bank analyst Sidney Ho raised the price target on Cree (NASDAQ: CREE) to $100.00 (from $60.00) while maintaining a Hold rating.... More

Apple (AAPL) and Microsoft (MSFT) Among 11 Stock Picked by Morgan Stanley as 'High Conviction Stocks' Ahead of Earnings

Morgan Stanley has outlined 11 stocks for which their analysts have a "high conviction" going into earnings season. Accordingly, one or more catalysts could help prices of these stocks to move higher in the next 15-60 days.

Overall, analysts believe that companies should beat estimates by at least 5%, which would make 4Q20 another quarter of sequential improvement. Following this quarter, the market is set to see a substantial rebound in earnings growth, according to the Chief US Equity Strategist, Michael Wilson.

The biggest positive contributor to projected earnings growth is Health Care, which is expected to grow 7%, with that... More